Biogen (BIIB) May Cut Jobs, Shutter Facilities to Streamline Ops and Free Up $400 Million for R&D
Eli Lilly (LLY) Shakes Up Cancer R&D Strategy, Seeks New Home for Seven Pipeline Drugs
Google (GOOG) Quietly Invests in This Cancer-Testing Startup, Builds Lab on Verily (GOOGL) Campus to Sweeten Deal
Japanese Pharma Giant Astellas (ALPMY) Sets Up Shop in Cambridge
Blood Clot Fears Delay Eli Lilly (LLY), Incyte (INCY)'s Potential Rheumatoid Arthritis Blockbuster, Stocks Fall
Merck & Co. (MRK) Dealt Another Setback as Its Ace Keytruda Comes Up Short in Head and Neck Cancer Study
Massachusetts’ Histogenics Looks to NeoCart for Replacing Knee Cartilage Loss
Mitsubishi Tanabe Coughs Up $1.1 Billion Cash for This Parkinson's Biotech
2 Tiny Cancer Biotechs That Could Gain Steam by Year-End
Boehringer Ingelheim Aims for 300 New Bay Area Jobs With $217 Million Expansion
5 Biotechs With $45 Billion Worth of Not-Yet Approved Drugs in the Pipeline
Brace Yourself: GlaxoSmithKline (GSK)'s New CEO Gets Ready to Overhaul the Drug Pipeline
Teva (TEVA) to Slash Up to 350 Employees in Reorg
Bay Area's Nektar (NKTR) Inks $400 Million+ Autoimmune Disease Pact With Eli Lilly (LLY)
AstraZeneca PLC (AZN) CEO Breaks Silence on Teva (TEVA) Rumors, Urges Staff to Remain Focused in Leaked Memo
10 Biotechs Tackling Senator John McCain's Form of Aggressive Brain Cancer
Texas Officials Lure Life Sciences Companies Like Merck & Co. (MRK), Which is Expected to Employ 600
Merz North America to Consolidate Three Facilities, Will Retain 165 Jobs and Hopes to Create More
See All News >
//-->